Stratum Biosciences Raises $2 Million in Seed Funding
Stratum Biosciences, a New York-based biotechnology company, has successfully secured $2 million in seed funding. This round was led by the Harvard Business School Alumni Angels of Greater New York, with additional investment from Skin Angels, a noted network of early-stage dermatology investors. Stratum Biosciences is known for leveraging artificial intelligence and biomarker discovery to develop innovative therapies and enhance molecular delivery through the skin.
Company Background
Co-founded in 2024 by dermatologist Dr. Ross Lane Pearlman and dermatopathologist Dr. Buu Duong, Stratum Biosciences operates at the intersection of AI and dermatology research. The company is focused on utilizing AI to analyze biological data, with the aim of revolutionizing skin therapy and product development.
Strategic Use of Funds
The $2 million raised will be primarily directed towards scaling Stratum's proprietary AI-powered skin biology discovery platform. This platform is capable of analyzing over 200,000 real skin samples to extract new insights and accelerate the development of dermatological products.
CEO Ross Pearlman highlighted the potential of modern AI in dermatology research, stating, "As a dermatologist, I see every day that the biggest gap in skin innovation is our limited understanding of skin biology. With modern AI, we can finally uncover the mechanisms hidden within skin that can translate into entirely new solutions to skin health."
Research and Development Focus
Stratum Biosciences plans to enhance its research and development partnerships, particularly with consumer packaged goods companies. The company aims to develop new active ingredients and formulations that offer improved delivery systems and bioavailability. Additionally, the focus will be on discovering new ingredient technologies targeting areas such as hyperpigmentation and skin longevity.
Technological Enhancements
The company is also part of NVIDIA’s Inception program, which provides access to advanced computing resources. This enables faster analysis of the extensive skin biopsy database, facilitating the discovery of novel biomarkers and mechanisms that are difficult to detect with traditional methods.
Looking Ahead
Based out of Johnson & Johnson’s JLABS incubator in New York, Stratum Biosciences is poised to further its mission of transforming skin health through cutting-edge AI and biomarker research. With the new funding, the company is well-positioned to make significant advancements in the field of dermatology, paving the way for novel therapeutic solutions.